Loading patent…
AssigneesAgenus Inc., Memorial Sloan Kettering Cancer Center, Ludwig Institute for Cancer Research
InventorsMarc VAN DIJK, Ekaterina V. BREOUS-NYSTROM, Volker SEIBERT, Gerd RITTER, David SCHAER, Daniel HIRSCHHORN-CYMERMAN, Taha MERGHOUB, Hao TANG, David A. SAVITSKY, Jeremy WAIGHT, Nicholas S. WILSON
Estimating the term…
The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
1-130. (canceled)
An isolated vector comprising a nucleic acid molecule encoding a heavy chain variable region (VH), wherein the VH comprises the amino acid sequence of SEQ ID NO:
An isolated vector comprising a nucleic acid molecule encoding a light chain variable region (VL), wherein the VL comprises the amino acid sequence of SEQ ID NO:
An isolated vector comprising a first and a second nucleic acid molecule, wherein the first nucleic acid molecule encodes a VH comprising the amino acid sequences of SEQ ID NO:
A host cell comprising a nucleic acid molecule encoding a VH, wherein the VH comprises the amino acid sequence of SEQ ID NO:
A host cell comprising a nucleic acid molecule encoding a VL, wherein the VL comprises the amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.